Prudential Financial Inc Corvus Pharmaceuticals, Inc. Transaction History

Prudential Financial Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.75 - $4.97 $24,772 - $32,831	-6,606 Reduced 30.66%	14,939 $0
Q4 2018 Feb 07, 2019	BUY	$3.29 - $8.94 $9,228 - $25,076	2,805 Added 14.97%	21,545 $79,000
Q3 2018 Nov 07, 2018	SELL	$8.58 - $11.4 $1,716 - $2,280	-200 Reduced 1.06%	18,740 $0
Q2 2018 Aug 13, 2018	BUY	$9.42 - $13.73 $178,414 - $260,046	18,940 New	18,940 $0

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.